April #100 : Looking for Liver Helpers - by Bob Roehr

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Archives » POZ Magazine issues

Table of Contents

Getting Out Alive

Last Call

He Said, He Said

Outside In

Myth vs. Reality in the Pen

The Hook-Up

Africa’s Mayor

3 x 5 Report Card

Tribute: Wilfredo Valencia Palacios Roman

Earthwatch: Prison Focus

Website of the month: AIDSVote.org

Medicare Malaise

See You in the Lobby

Show & Tell: Oscar Time



Cirque du So Lame

Can HIV Care Click in the Clink?

A Bitter Pill

Comfort Zone: SpiceBoy

The Sweetest Taboo

Diamond in the Roughage

Head Games

Looking for Liver Helpers

Quick Study: Painkiller


Cheek to Chic

Warning Signs

Quick Study: Sexual Satisfaction

Publisher’s Letter


Live To Tell: With Conviction

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

email print

April 2004

Looking for Liver Helpers

by Bob Roehr

About 40 percent of HIVers are coinfected with hep C, and so far, interferon’s the only hepatitis C (HCV) treatment. It “trains” the immune system to respond to the virus—and can deliver some sickening side effects. HCVers and docs hope treatment can get shorter and easier to tolerate with the addition of new meds such as these early-development dandies:

Two HCV Protease Inhibitors

>> BILN 2061. In early trials, people with genotype 1 virus (most common in the U.S.) seem to respond well to this drug.

>> VX-950. Still in the lab, it looks stronger and less vulnerable to resistance than BILN. Human trials start early this year.

Reality check: “A lot of the PIs bomb” in more advanced trials, says New York City liver pro Douglas Dieterich, MD, who cautions that interferon plus ribavirin may remain the standard for at least another decade.

Just a spoonful of Albuferon makes the interferon stick around:

>> While awaiting PIs: Albuferon fuses human albumin (think egg whites) onto interferon to keep your body from filtering out the drug. Dieterich hopes Albuferon can steady the body’s drug level, allowing for less drug and fewer side effects and letting HCVers get a shot every two to four weeks (vs. once-a-week Pegasys and Peg-Intron).

In early Phase I/II trials, HCVers who didn’t respond to pegylated interferon saw encouraging declines in HCV viral load on Albuferon. Next step: finding the best dose for a full Phase III trial this year.

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Has a pet helped you deal with your HIV?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.